Collegium Reports Q1 2026 Earnings with Revenue Growth
Collegium (COLL) reported total net product revenues of $193.5 million for the first quarter of 2026, a 9% increase year-over-year driven by growth in its ADHD and pain portfolios. JORNAY revenue rose 36%, while Belbuca and Xtampza ER also contributed to gains.
Tickers: $COLL
Topics: ebitda pharmaceuticals revenue_growth